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Abstract
Background: Rett syndrome (RTT) is a rare neurodevelopmental disorder associated with pathogenic MECP2 variants. Because the MECP2 gene is subject to
X-chromosome inactivation (XCI), factors including MECP2 genotypic variation,
tissue differences in XCI, and skewing of XCI all likely contribute to the clinical
severity of individuals with RTT.
Methods: We analyzed the XCI patterns from blood samples of 320 individuals
and their mothers. It includes individuals with RTT (n = 287) and other syndromes sharing overlapping phenotypes with RTT (such as CDKL5 Deficiency
Disorder [CDD, n = 16]). XCI status in each proband/mother duo and the parental origin of the preferentially inactivated X chromosome were analyzed.

†This work is dedicated to the memory of Dr. Mary Jones, who passed away recently.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
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Results: The average XCI ratio in probands was slightly increased compared to
their unaffected mothers (73% vs. 69%, p = .0006). Among the duos with informative XCI data, the majority of individuals with classic RTT had their paternal allele
preferentially inactivated (n = 180/220, 82%). In sharp contrast, individuals with
CDD had their maternal allele preferentially inactivated (n = 10/12, 83%). Our
data indicate a weak positive correlation between XCI skewing ratio and clinical
severity scale (CSS) scores in classic RTT patients with maternal allele preferentially inactivated XCI (rs = 0.35, n = 40), but not in those with paternal allele
preferentially inactivated XCI (rs = −0.06, n = 180). The most frequent MECP2
pathogenic variants were enriched in individuals with highly/moderately skewed
XCI patterns, suggesting an association with higher levels of XCI skewing.
Conclusion: These results extend our understanding of the pathogenesis of RTT
and other syndromes with overlapping clinical features by providing insight into
the both XCI and the preferential XCI of parental alleles.
KEYWORDS

CDKL5 deficiency disorder, MECP2, preferential inactivation of parental alleles, Rett
syndrome, X-chromosome inactivation

1

|

I N T RO DU CT ION

Rett syndrome (RTT) [MIM: 312750] is a rare, X-linked
neurodevelopmental disorder. Individuals with RTT
have apparently normal development for the first 6 to
18 months of life followed by a period of developmental
stagnation and neurological regression (Jeffrey L. Neul
et al., 2010; Percy et al., 2010). Characteristic repetitive,
stereotypic hand movements, abnormal or absent speech,
and abnormal or absent fine motor skills and ambulation
are required in the diagnosis of classic RTT and may be
accompanied by microcephaly, intellectual disability,
breath-holding, and hyperventilation while awake, scoliosis, and seizures. RTT almost exclusively affects females,
with a prevalence of about 1 in 10,000 females by 12 years
of age (Laurvick et al., 2006). Pathogenic, loss-of-function
variants in the X-
linked MECP2 [MIM: 300005] gene,
which encodes the methyl-CpG binding protein 2, are
present in 95%–97% of individuals meeting the criteria for
classic or typical RTT (Lyst & Bird, 2015; Neul et al., 2010).
The majority of pathogenic variants in the MECP2 gene
occur de novo (Hampson et al., 2000; Huppke et al., 2000;
Yamashita et al., 2001), with parental studies indicating
that up to 96% of these alterations occur on paternal allele
(Girard et al., 2001; Trappe et al., 2001; Zhu et al., 2010).
Rare males with MECP2 pathogenic variants present
with variable features, ranging from developmental
delay to early infantile epileptic encephalopathy (Budden

et al., 2005; Chahil et al., 2018; Neul et al., 2019; Reichow
et al., 2015).
Variant or atypical RTT, representing about 13% of
individuals with RTT, must meet two of four necessary
criteria and five of 11 supportive criteria for a clinical
diagnosis (Neul et al., 2010; Percy et al., 2007). Whole
gene duplication of MECP2 causes a severe neurodevelopmental phenotype characterized by developmental
delay, infantile hypotonia, seizures, feeding difficulty,
poor or absent speech, and history of recurrent infections (del Gaudio et al., 2006; Peters et al., 2019). This
disorder is separately classified as MECP2 duplication
syndrome and occurs mainly in males. Other syndromes, such as developmental and epileptic encephalopathy type 2 [MIM: 300672], may display overlapping
phenotypes with classic RTT symptoms but are caused
by pathogenic variants in genes other than MECP2.
Pathogenic variants in cyclin-dependent kinase-like 5
(CDKL5) [MIM: 300203], also X-linked, and forkhead box
G1 (FOXG1)[MIM: 164874], an autosomal gene, result
in the neurodevelopmental disorders CDKL5 deficiency
disorder (CDD) (Weaving et al., 2004) and FOXG1 disorder (FD) [MIM: 613454] (Ariani et al., 2008; Kortüm
et al., 2011; Mitter et al., 2018; Olson et al., 2019), respectively. Although these disorders were originally
considered with Rett-like phenotypes, they are now regarded as unique disorders based on their clinical features and molecular etiologies.
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X-
chromosome inactivation (XCI) is a DNA
methylation-mediated gene-silencing process unique to
the X chromosome, which ensures appropriate dosage
compensation between the sexes in mammals (Augui
et al., 2011; Duncan et al., 2018; Patrat et al., 2020). In
females, inactivation of one or the other X chromosome
occurs early in development and is, in general, a random
process (Cohen et al., 2003; Wu et al., 2014). As a result,
females inherently have a mosaic pattern of active and
inactive X chromosomes in cells throughout the body
(Migeon, 2007). XCI skewing occurs when one X chromosome is preferentially inactivated over the other in a
nonrandom manner. XCI skewing may be caused by the
presence of a mutation in an X-linked gene, usually resulting in preferential inactivation of the X chromosome
containing the mutant allele, and/or the presence of X-
linked mutations that confer a selective advantage or disadvantage to the cells (Brown & Robinson, 2000; Migeon
et al., 1981; Plenge et al., 2002). Previous reports have
found ~8.8%–10% of healthy females with an XCI skewing
ratio > 80%, and ~ 2% with an XCI skewing ratio > 90%
(Amos-Landgraf et al., 2006; Shvetsova et al., 2019).
Since the MECP2 gene is subject to XCI, phenotypic
variability may be influenced by skewed XCI when a
pathogenic variant exists on one of its alleles. While most
RTT cases are sporadic, unaffected mothers that carry
MECP2 pathogenic variants have been reported, likely
protected by highly skewed inactivation of the X chromosome carrying the mutant allele (Wan et al., 1999).
Previous studies investigating the parental origin of the
inactivated X chromosome in RTT individuals identified
the paternally inherited X chromosome as preferentially
inactivated in skewed cases (Knudsen et al., 2006). As
the majority of de novo MECP2 alterations occur on the
paternal allele (Girard et al., 2001; Trappe et al., 2001;
Zhu et al., 2010), this could indicate that a relatively
small proportion of cells expressing the mutated copy
of MECP2 can result in RTT in affected individuals
with highly skewed XCI patterns. Conversely, inherited
MECP2 mutations are mostly on the maternally inherited X chromosome, which results from either skewing of
XCI in the asymptomatic mother or germline mosaicism
(Venâncio et al., 2007).
In this study, we analyzed XCI patterns in 320 participants with RTT or RTT-related syndromes and their unaffected mothers from the Natural History of Rett Syndrome
& Related Disorders study (NCT02738281). We sought to
identify parent-of-origin skewing patterns in the probands
and to determine if any relationship exists between the
levels of XCI skewing and known mutational status in either MECP2 or CDKL5 gene. These results are intended to
provide further insight into the pathogenesis of RTT and
RTT-related syndromes
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MATERIALS AND METHO D S
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Subjects

Peripheral blood samples from 320 duos of RTT or RTT-
related syndromes participants and their mothers were
collected from the Natural History of Rett Syndrome &
Related Disorders (NCT02738281) and Biobanking of Rett
Syndrome and Related Disorders (NCT02705677) studies.
The MECP2 (NM_004992.4) or CDKL5 (NM_003159.3)
variants in each patient are listed in Table S1. The biologic
samples were collected under the biobanking protocol approved by the relevant Institutional Review Boards of the
Rett Syndrome and Related Disorders consortium.

2.2

|

DNA preparation and XCI analysis

Genomic DNA from each individual was extracted from
peripheral blood using conventional DNA isolation methodology. The XCI pattern was determined by PCR analysis
of a polymorphic trinucleotide repeat in the first exon of
the androgen receptor (AR) gene with or without digestion
with the methylation-sensitive enzyme HpaII (Pegoraro
et al., 1994). All samples were analyzed as proband-
mother pairs. Degree of XCI skewing was calculated as the
fractional peak area ratio (expressed as %) for the more
strongly amplified allele. Degree of skewing thus varies
between 50% and 100%, where 50% reflects a random pattern and 100% a completely skewed pattern. Samples with
skewing ratio below 80% were classified as “Randomly
inactivated”, 80%–90% as “Moderately skewed”, and 91–
100% as “Highly skewed”. The cutoff was set based on the
XCI skewing distribution in healthy individuals (Amos-
Landgraf et al., 2006; Shvetsova et al., 2019). If an individual was homozygous for their AR allele sizes, the XCI
status was interpreted as “Uninformative”. If results could
not be determined due to poor sample quality, the XCI status is interpreted as “No result”. Samples with borderline
ratios (78%–82% and 89%–93%) were repeated in duplicate
and the final ratio was generated based on the average
from all three analyses.
AR repeat allele sizes were analyzed and the specific allele with XCI rate over 50% was considered preferentially
inactivated in the individual. Parental origin of the inactivated X chromosome in the probands was assessed by
comparison of AR repeat allele sizes in probands and their
mothers. If the two alleles had the same XCI rate (i.e., 50%),
the parental origin was interpreted as “Uninformative”.
If the preferentially inactivated allele was found in the
mother, while the other allele (active allele) of the proband
was not found, the preferentially inactivated allele was interpreted as “Maternal”. If the preferentially inactivated
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allele was not found in the mother, while the other allele
(active allele) of the proband was found, it was extrapolated and interpreted to be “Paternal”. If both proband and
mother shared the same two alleles (of either same or different AR repeat sizes), the parental origin was interpreted
as “Uninformative”.

|

2.3

Statistical data analysis

Statistical analysis was performed by student t-test (two-
tail, paired comparison) for duos (mother and proband).
For correlation analysis of clinical severity and parental
ages, Pearson and Spearman correlation coefficients were
measured and p value was generated based on standard
procedure. Normal probability distribution was generated
by Microsoft Excel. The variant analysis in probands was
performed by student t-test (two-tail, unequal variance).

3

|

R E S U LTS

3.1 | Clinical characteristics of
participants
The RTT Natural History cohort used in this study
consisted of individuals with classic RTT (261/320 individuals), atypical RTT (26/320 individuals), MECP2 duplication disorder (2/320 individuals), CDD (16/320), and
individuals with a MEPC2 mutation but not meeting criteria for either classic or atypical RTT (non-RTT MECP2)
(15/320). Of 320 probands, we were able to obtain XCI results for 263 with informative parental allele inactivation
status (Figure 1 and Table 1).

FIGURE 1

Flowchart of the study. XCI, X-chromosome inactivation

3.2 | Differences in parental origin of
XCI skewing in individuals with classic
RTT versus CDD
The maternal XCI pattern was studied along with each
proband's XCI pattern for individuals with informative results with classic RTT (n = 220), and the parental origin
of the inactivated allele was determined as described in
Materials and Methods section. For the individuals with
classic RTT, the majority (82%, 180/220) had their paternal allele preferentially inactivated (Figure 2a, Table 2).
In contrast, among individuals with CDD, most probands
(83%, 10/12) had their maternal allele preferentially inactivated (Figure 2a, Table 2). Individuals with atypical RTT
(58%, 11/19) or non-RTT MECP2 (54%, 6/11) showed intermediate ratio of paternal allele XCI.
In the probands with highly/moderately skewed XCI,
the same preferential XCI patterns were observed (for
classic RTT, 95% (77/81) paternally skewed; for CDD, 0%
(0/3) paternally skewed; for atypical RTT, 63% (5/8) paternally skewed; for non-RTT MECP2, 0% (0/2) paternally
skewed) (Figure 2b, Table 2).

3.3 | Identification of XCI patterns in the
RTT natural history cohort
For probands with classic RTT, 20 were highly skewed,
69 were moderately skewed, and 151 individuals had random XCI (Table 3). For the CDD participants, none of
those with informative results displayed highly skewed
inactivation, while three individuals had moderately
skewed inactivation and 12 had random inactivation. The
average XCI skewing ratio was 73.1 ± 1.3% (Mean ± SEM,

Fang et al.
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Summary of the total number of probands and the resulting number available for X-chromosome inactivation (XCI) analysis
XCI
informative

Proband XCI
uninformative

Proband no
XCI results

Insufficient
diagnosis
information

Mother XCI
uninformative

Total

263

24

4

5

29

Classic RTT

220

19

2

n/a

n/a

Atypical RTT

19

2

1

n/a

n/a

MECP2 duplication

1

1

0

n/a

n/a

CDD

12

1

0

n/a

n/a

Other MECP2-positive variant but non RTT

11

1

1

n/a

n/a

Abbreviations: CDD, CDKL5 deficiency disorder; RTT, Rett syndrome.

F I G U R E 2 Parental origin analysis of
preferentially inactivated X-chromosome
allele in individuals with classic RTT
and CDD. (a) XCI ratio (randomly,
moderately, and highly skewed) of
individuals with informative parental
origin status of preferentially inactivated
parental allele. (b) Individuals with
highly or moderately skewed XCI and
preferentially inactivated parental allele.
XCI, X-chromosome inactivation; RTT,
Rett syndrome; CDD, CDKL5 deficiency
disorder

T A B L E 2 Parent of origin of
preferentially inactivated X-chromosome
Totala

Probands

Paternal
allele
inactivated

Maternal
allele
inactivated

Classic RTT

220

180

40

Atypical RTT

19

11

8

MECP2 duplication

1

0

1

Other MECP2-positive variant but non
RTT

11

6

5

With CDKL5 variant

12

2

10

Abbreviation: RTT, Rett syndrome.
a

Total number of probands with informative XCI results for both proband and mother.

n = 297) in the probands, and 68.8 ± 1.3% (Mean ± SEM,
n = 292) in their unaffected mothers, which was determined to be significant (p = .0006, student t-test, paired

comparison). The percentage of mothers with highly/
moderately skewed XCI, regardless of their daughter's
XCI status, was 22% (64/292).
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3.4 | Association between XCI skewing
patterns and clinical severity
To confirm whether there is any association between
clinical severity and XCI skewing ratios, we performed
a correlation analysis using clinical severity scale (CSS)
and motor behavior analysis (MBA) (Lane et al., 2011)
in patients with classic RTT. Overall, there is no correlation between XCI ratio and CSS (coefficient = −0.02,
n = 240) or MBA (coefficient = 0.05, n = 116). However,
in the probands with maternally inactive alleles, there is a
weak positive correlation between XCI ratio and CSS (coefficient = 0.35, n = 40), and similar correlation between
XCI ratio and MBA (coefficient = 0.30, n = 17) (Figure 3,

T A B L E 3 The skewing ratio distribution of individuals with
classic RTT or CDD disorders
Inactivation
ratio
interpretation

Skewing ratio
range (%)

Classic RTT
(n = 240)

CDD
(n = 15)

91–100

20 (8%)

0 (0%)

Highly skewed

80–90

69 (29%)

3 (20%)

Moderately
skewed

70–79

63 (26%)

3 (20%)

60–69

46 (19%)

6 (40%)

Randomly
inactivated

50–59

42 (18%)

3 (20%)

Abbreviations: CDD, CDKL5 deficiency disorder; RTT, Rett syndrome.

Tables S1 and S2), which indicates that increased XCI
might be correlated with stronger phenotypes in those
individuals. This correlation was not found in probands
with paternal allele preferentially inactivated (Figure 3).
No definite correlation between XCI ratio and clinical severity was observed in probands with highly/moderately
skewed XCI. Other factors, such as potential modifier
gene variants, might also influence the XCI-clinical severity associations and are not taken into account in the current analysis.

3.5

|

Molecular genotype and XCI

MECP2 pathogenic variants and their genotype–
phenotype association with RTT have been recorded by
multiple databases and summarized by different groups
(Ehrhart et al., 2021). The mutational status of this cohort was known prior to current study, with 58 unique
MECP2 alterations (large deletions were grouped together as one variant type) and 16 unique CDKL5 alterations (Table S3). The spectrum of pathogenic variants
in the probands with highly/moderately skewed XCI
consisted of 22 unique MECP2 and three CDKL5 alterations (Table 4). Eight of the 22 MECP2 alterations were
recurrent, while all CDKL5 changes were only observed
once (Table 4). The eight recurrent MECP2 pathogenic
variants are among the most commonly reported in individuals with RTT (Williamson & Christodoulou, 2006)

F I G U R E 3 Clinical severity scale (CSS) and motor behavior analysis (MBA) scores were used to evaluate the clinical severity in
probands with classic RTT. Correlation analysis between clinical severity and XCI in all probands combined, probands with paternal allele
preferentially activated, and probands with maternal allele preferentially inactivated revealed weak positive correlation between XCI
skewing ratio and CSS scores in individuals with maternal allele preferentially inactivated XCI (rs = 0.35) but not in those with paternal
allele preferentially inactivated XCI (rs = −0.06). Dotted trendline is shown for each plot. XCI, X-chromosome inactivation; RTT, Rett
syndrome

Fang et al.
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MECP2 and CDKL5 variants in individuals with highly/moderate skewing XCI

MECP2 variants

Number of probands with the specific
variant

Percentage of pathogenic
mutations reported (Williamson &
Christodoulou, 2006)

MECP2 c.502C > T (p.Arg168Ter)

7 (13.5%)

11.90%

MECP2 c.763C > T (p.Arg255Ter)

7 (13.5%)

10.70%

MECP2 c.808C > T (p.Arg270Ter)

6 (11.5%)

9.60%

a

5 (9.6%)

N/A

MECP2 c.880C > T (p.Arg294Ter)

4 (7.7%)

8.20%

MECP2 LargeDel

MECP2 c.316C > T (p.Arg106Trp)

3 (5.8%)

4.80%

MECP2 c.916C > T (p.Arg306Cys)

3 (5.8%)

6.40%
12.20%

MECP2_c.473C > T (p.Thr158Met)

3 (5.8%)

MECP2 c.1164_1207del (p.Pro389Ter)

1 (2%)

MECP2 c.1308_1309del (p.Gln437AlafsTer49)

1 (2%)

MECP2 c.430A > T (p.Lys144Ter)

1 (2%)

MECP2 c.57_58ins17

1 (2%)

MECP2 c.806del (p.Gly269AlafsTer20)

1 (2%)

MECP2 c.856_859del (p.Lys286ProfsTer2)

1 (2%)

MECP2 c.1081_1310del (p.Pro361AlafsTer49)

1 (2%)

MECP2 c.1163_1188del (p.Pro388ArgfsTer8)

1 (2%)

MECP2 c.454C > G (p.Pro152Ala)

1 (2%)

MECP2 c.514_515insA (p.Pro172HisfsTer3)

1 (2%)

MECP2 c.455C > G (p.Pro152Arg)

1 (2%)

MECP2 c.622C > T (p.Gln208Ter)

1 (2%)

MECP2 c.917G > A (p.Arg306His)

1 (2%)

MECP2 c.423C > G (p.Tyr141Ter)

1 (2%)

CDKL5 variants

Frequency

CDKL5 c.626C > G (p.Pro209Arg)

1

CDKL5 c.784 T > C (p.Tyr262His)

1

CDKL5 Deletion Xp22.13(18,401,075-18,455,975)

1

Non-RTT with MECP2 alteration

Present in highly/
moderately skewed cases

MECP2 c.1164_1207del (p.Pro389Ter)

Yes

MECP2 c.1328C > T(p.Ala443Val)

No

MECP2 c.808C > T (p.Arg270Ter)

Yes

MECP2 c.923C > T (p.Thr308Ile)

No

MECP2 c.1151_1195del45 (p.Pro385_Pro399del)

No

MECP2 c.1135_1142del (p.Pro379ThrfsTer11)

No

MECP2 c.487G > T (p.Gly163Trp)

No

MECP2 c.397C > T (p.Arg133Cys)

No

MECP2 c.433C > T (p.Arg145Cys)

No

Notes: MECP2 (NM_004992.4) and CDKL5 (NM_003159.3) were used.
Abbreviations: RTT, Rett syndrome; XCI, X-chromosome inactivation.
a

Large intragenic deletions are grouped as one variant type.

(Table 4). The percentage of individuals with those eight
variants was increased in the highly/moderately skewed
XCI group compared to randomly inactivated XCI group

(mean 9.1% vs. 6.7%, p = .03) (Table 5). This suggests
a potential enrichment of the recurrent MECP2 variants in individuals with highly/moderately skewed XCI
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TABLE 5

Recurrent MECP2 variants found more often in individuals with skewed XCI patterns (high/moderate vs. random, p = .03)
% of highly/moderately skewed XCI group (n = 52)

% of random inactivation
group (n = 92)

MECP2 p.Arg168Ter

13.5% (7)

8.7% (8)

MECP2 p.Arg255Ter

13.5% (7)

9.8% (9)

MECP2 p.Arg270Ter

11.5% (6)

7.6% (7)

MECP2 LargeDel

9.6% (5)

5.4% (5)

MECP2 p.Arg294Ter

7.7% (4)

3.3% (3)

MECP2 p.Arg106Trp

5.8% (3)

2.2% (2)

MECP2 p.Arg306Cys

5.8% (3)

7.6% (7)

MECP2 p.Thr158Met

5.8% (3)

8.7% (8)

Average

9.1% (4.7)

6.7% (6.2)

Note: MECP2 (NM_004992.4) was used.
Abbreviation: XCI, X-chromosome inactivation.

patterns, indicating that those variants might be associated with higher levels of XCI skewing. We performed
a similar analysis for the probands with both MECP2
variant and X-inactivation results in RettBASE database (Krishnaraj et al., 2017). Among all the qualified
probands (n = 265), 91 were with highly/moderately
skewed XCI and 174 with random XCI (Table S4). In
addition to the eight recurrent variants reported in our
cohort, there were three more variants (R133C, P389X,
and R106W) which were reported for multiple times in
both random XCI group and highly/moderately skewed
XCI group. These 11 recurrent variants comprised 74.7%
of all the variants found in probands with highly/moderately skewed XCI, while comprising 55.2% in those with
random XCI. Thus, the increased prevalence of recurrent MECP2 variants with highly/moderately skewed
XCI in our study is consistent with the larger RettBASE
cohort. However, some caution is warranted in making
direct comparisons from our XCI data to data generated
in different labs, considering that different methods and
cutoff values might introduce potential bias in patients
tested in the RettBASE database.
Next, we wanted to determine if probands with MECP2
pathogenic variants and highly/moderately skewed XCI
also had mothers that display highly/moderately XCI
skewing. Overall, we found 52 probands with highly/
moderately skewed XCI patterns and MECP2 variants
(Table S1). Notably, 12 of these probands have mothers
who also exhibited highly/moderately skewed XCI patterns, a ratio that is close to previously published data
(23% (12/52) in this study, 21% (3/14) by Knudsen et al.)
(Knudsen et al., 2006).
To further analyze the pathogenic MECP2 variants
based on their clinical severity, we classified the variants into two groups, Severe and Mild (Table S5). The
Severe group includes severe mutations, such as R016W,

R168X, R255X, R270X, early truncations (before R270),
and large deletions. The Mild group includes less severe mutations such as R133C, R294X, R306C, and C-
terminal truncation. In individuals with classic RTT,
XCI ratio was slightly increased in Severe group (n = 64)
compared to Mild group (n = 29), yet the difference was
not significant (student t-test, 75.8 vs. 72.5 [Severe vs.
Mild], p = .23, Table S5). CSS and MBA scores were both
increased in Severe group (CSS, 26.2 vs. 21.9, p = .01;
MBA, 51.7 vs. 46.5, p = .06), which is expected (Table S5).
More probands with highly/moderately skewed XCI pattern were observed in Severe group compared to Mild
group (42.19% vs. 31.03%). There is no significant difference among probands with highly/moderately skewed
XCI and those with random XCI based on their CSS or
MBA scores when they are from the same severity group
(Table S5).

3.6 | Association between XCI skewing
patterns and specific MECP2 and CDKL5
alterations
We compared the XCI patterns between individuals
with MECP2 and CDKL5 pathogenic variants. The average XCI ratio of those with MECP2 variants was 73.2%,
while those with CDKL5 variants was 68.0%. We then
evaluated the possible correlation between genetic etiology and degree of XCI skewing. Out of all the probands
with highly/moderately skewed XCI, 52 had variants
in MECP2 (45 classic RTT, six atypical RTT, and one
non-RTT MECP2), and three had variants in CDKL5
(Table 6). Among those with MECP2 pathogenic variants and highly/moderately skewed XCI patterns, 44
exhibited inactivation of the paternally inherited allele (12 highly skewed, 32 moderately skewed) and four
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T A B L E 6 Clinical distribution of individuals with highly or
moderately skewed XCI
Highly/moderately skewed
probands/Total probandsa (%)
With MECP2 variant

52/129 (40%)

With CDKL5 variant

3/12 (25%)

Classic RTT

45/113 (40%)

Atypical RTT

6/8 (75%)

MECP2 duplication

0/1 (0%)

Other MECP2-positive
variant but non RTT

1/7 (14%)

Abbreviations: RTT, Rett syndrome; XCI, X-chromosome inactivation.
a
Total number of probands with informative XCI results for both proband
and mother.

exhibited inactivation of the maternally inherited allele
(all moderately skewed). The three individuals with
CDKL5 pathogenic variants showed preferential inactivation of the maternal allele (Tables 6 and S1).
Among those with pathogenic MECP2 variants yet no
features of RTT (non-RTT MECP2), two had preferential
inactivation of the maternal allele and five of the paternal
allele. Only one participant with MECP2 duplication syndrome had an XCI result. This individual and her mother
both had a random XCI pattern, and the proband had inactivation of the maternal allele (Table S1, Family 156).
The same allele was inactivated in the mother. This patient has MECP2 triplication and her mother is confirmed
to be normal (no duplication) by chromosomal microarray
analysis.
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DI S C USSION

In this study, we describe the XCI skewing patterns of
a large cohort of individuals with RTT and RTT-related
syndromes from the Natural History of Rett Syndrome
& Related Disorders study. The percentage of probands
with classic RTT and highly/moderately skewed XCI
(>80:20 XCI ratio) was 37.1% (89/240 individuals). This
result is in line with data from a previously studied yet
unpublished cohort from the same natural history study,
in which 44% of probands (no sample from mothers
available) with classic RTT were found to have highly/
moderately skewed XCI (59/133 individuals, Table S1).
We also determined the percentage of mothers with
highly/moderately skewed XCI, regardless of their
daughter's XCI status, to be 22%. These two percentages are increased from the observed highly/moderately
skewed XCI ratio percentages of 5% and 14% in phenotypically unaffected newborns and adults, respectively
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(Amos-Landgraf et al., 2006), which represents a statistical difference. The increased percentage of mothers
with highly/moderately skewed XCI observed in this
study is consistent with a previous report of mothers of
individuals with RTT (Knudsen et al., 2006); however,
the mechanism and significance of this finding remain
unclear.

4.1 | Differences in parental origin of
preferentially inactivated X chromosomes
between classic RTT and CDD
One advantage of this study is that maternal samples
were available to determine the parent of origin of the
preferentially inactivated X chromosome for probands
with RTT or RTT-related syndromes (particularly CDD).
Our finding that classic RTT individuals have preferential
skewing of their paternal allele is concordant with previous studies (Knudsen et al., 2006; Nielsen et al., 2001).
Although the number of individuals in this study with
CDD was considerably smaller than those with classic
RTT, a sharp contrast was observed for the parental origin of the preferentially inactivated X chromosome, with
the majority of CDD probands showing preferential inactivation of the maternal allele (Figure 2).
The finding that the paternal X chromosome is preferentially inactivated in probands with classic RTT is
consistent with the expected finding that up to 96% of
de novo MECP2 alterations occur on the paternal allele
(Girard et al., 2001; Trappe et al., 2001; Zhu et al., 2010),
and suggests that only a small portion of cells expressing
the variant-carrying allele is necessary to produce clinical RTT symptoms. One potential explanation for preferential inactivation of the paternal X chromosome in
RTT could be due to a survival advantage in blood cells
that inactivate X chromosomes with MECP2 pathogenic
variants. Blood samples, by default, serve as a proxy for
XCI in brain tissue, which is the critical tissue for individuals with RTT. A few studies, with smaller sample
sizes, have performed XCI studies on brain tissue from
individuals with Rett syndrome (Shahbazian et al., 2002;
Zoghbi et al., 1990). In these studies, only random patterns of XCI were observed in the brain tissue of these
individuals (n = 10 and n = 3). Zoghbi et al. examined
the XCI pattern of both neuronal and nonneuronal tissue of the same individuals, and, interestingly, varying
degrees of skewing were observed in the nonneuronal
tissue, while XCI in brain tissue was random for all three
(Zoghbi et al., 1990).
Currently, little is known about the parental origin of
the inactivated X chromosome in individuals with CDD,
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and, to our knowledge, this is the first study that examines parental origin of XCI in CDD probands. While our
initial results suggest a difference in the XCI patterns
between individuals with MECP2 and CDKL5 pathogenic variants, further studies are required to examine
a larger cohort with CDKL5 pathogenic variants and
confirm this observation and its potential relationship
to pathogenicity.

4.2 | Association between MECP2
genotype and XCI skewing
Since the probands in this RTT Natural History study
had previous genetic testing results, we investigated
the relationship between genotype and X-inactivation
pattern. While certain MECP2 pathogenic variants
were seen in multiple individuals with highly/moderately skewed XCI patterns, these alterations are
among the most common changes observed in individuals with RTT (Table 4). Additionally, the common p.R270X pathogenic variant was also identified
in probands with a moderate pattern of XCI and without RTT features (Williamson & Christodoulou, 2006)
(Table 4). The percentage of individuals with the eight
common variants was increased in the highly/moderately skewed XCI group compared to the random XCI
group. These results suggest the common/recurrent
MECP2 variants might be associated with higher levels of XCI skewing. Interestingly, based on the weak
positive correlation between skewing ratio of XCI and
clinical severity in the probands with maternal allele
inactivation, it is possible that in those individuals, the
cells with higher ratio of XCI skewing would cause a
more severe phenotype. Given that the maternal allele
is inactivated and the paternal allele is active, the de
novo pathogenic variants in each individual (located
presumptively on paternal allele) would be expressed
more than the wild-type allele, consequently causing
a more destructive effect on the cell growth and survival. Conversely, in probands with paternal allele inactivated, the maternal allele is active, and the skewing
ratio has less of an effect, since wild-type MECP2 expression is increased over mutant MECP2 expression.
Nevertheless, based on XCI and clinical data presented
in this study, the amount of mutant MECP2 expression
still has an effect on clinical outcome of these individuals, which suggests that a small amount of cells with
defective MECP2 can be enough to cause severe clinical phenotype. The timing and location of the cells expressing defective MECP2 might also contribute to the
clinical severity.
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4.3 | Effects of XCI status on clinical
severity in RTT and CDD based on
proportion of cells expressing active
mutated allele
Given the literature that most of the MECP2 variants
in RTT are de novo (Hampson et al., 2000; Huppke
et al., 2000; Yamashita et al., 2001), and most of the de
novo variants are on the paternal allele (Girard et al., 2001;
Trappe et al., 2001; Zhu et al., 2010), the paternal allele is
therefore assumed to carry the MECP2 pathogenic variants in the majority of RTT cases. The observed preferential inactivation of the paternal allele seems to be the
result of a protective mechanism against the mutated allele, by natural selection of the cells with skewed XCI of
the paternal allele. However, it is interesting that an individual who is highly skewed toward inactivating the paternal (presumably mutant) chromosome still displays the
clinical features of RTT, which is suggested by our data.
One possible explanation is that the effect of specific
pathogenic variants might be much larger than XCI, and
only a small portion of cells expressing the active mutant
allele would be required for clinical manifestation, although it might be difficult to detect the specific effect of
XCI with various MECP2 variants. By stratifying specific
mutations, Archer et al. analyzed the correlation between
clinical severity in individuals with RTT with two MECP2
pathogenic variants, and found a statistically significant
increase in clinical severity with increase in the proportion of active mutated allele (Archer et al., 2007).
Another possibility is that there might be other genetic
modifiers that modulate the phenotypic expression. In the
group of non-RTT MECP2, we analyzed individuals with
pathogenic MECP2 variants, who do not have RTT and
demonstrate a milder phenotype without regression. The
typical expectation is that these people would be highly
skewed favoring the maternal/wild-type allele and skewing
level might also depend on variants. Yet, our results showed
that the percentage of inactivated paternal allele (55%,
n = 6/11) is smaller than that of the individuals with classic
RTT (82%, n = 180/220). In individuals with highly/moderately XCI skewing, the results were even more striking, with
neither of the non-RTT MECP2 individuals (0/2) showing
skewed XCI of paternal allele, versus 95% in classic RTT
(77/81). Some of the variants in the non-RTT MECP2 group
are not common and may have milder functional consequences (e.g., R145C, G163W, A443V), but other more severe variants, such as R133C and R270X, could disrupt all of
the function of the protein (Ballestar et al., 2000; Yusufzai &
Wolffe, 2000). It is surprising that the mutant alleles are not
markedly skewed in the non-RTT MECP2 individuals and
that these individuals do not display the RTT phenotypes.
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Previous work failed to find significant clinical severity differences between males and females with
CDKL5 pathogenic variants (Demarest et al., 2019; Fehr
et al., 2016; MacKay et al., 2021), which was counterintuitive to researchers' expectation, as random XCI could
have provided more variability and possibly milder clinical phenotypes in females. The finding that individuals
with CDD tend to have maternal allele preferentially inactivated might provide insight into that unusual observation. That is, to manifest CDD, individuals need to have
a majority of the cells in the body/brain expressing the
pathogenic variant of CDKL5, and when there is random
XCI in females with CDKL5 pathogenic variants, they do
not manifest the entire CDD phenotype, and appear to
be unaffected or asymptomatic. This could explain why
a marked severity difference is not noted between males
and females with CDD, as only the females with a high
proportion of active mutated alleles would show a clinical phenotype, similar to the males with all the cells expressing the mutated allele of CDKL5. This finding also
has implications for the potential of an unrecognized pool
of females with CDKL5 pathogenic variants that are not
being identified because of the observational bias in conducting genetic testing.

4.4 | Limitations, pitfalls, and future
perspectives
An important caveat to this study, and most XCI studies,
is that the assays were performed in DNA from peripheral
blood, which is not typically the affected tissue(s) in X-
linked disorders, such as RTT. Recently, Tukiainen et al.
assessed XCI across human tissues based on RNA-seq, and
demonstrated that the X-inactivation patterns are usually
consistent across tissues, despite a few variable escapee
behaviors (Tukiainen et al., 2017). These data suggest that
blood samples could serve as a reliable nonneuronal tissue to determine XCI. However, it does not rule out the
probability that a certain level of discordant XCI skewing
exists in different tissues in individuals. Further studies
with larger sample sizes involving both neural and nonneural tissues would be helpful to overcome the limitation
of interpretation based on blood XCI status reflecting that
of brain or other tissues, and explain the possible discordance of XCI status among different tissue types.
Another limitation in this study is the small cohort size
of individuals with CDD. CDD has an incidence of 1 in
40,000 to 60,000 newborns, which makes it rarer than RTT
and leads to an overall smaller patient population compared to RTT. As more patients with CDD are identified
and their XCI status examined, a more thorough statistical analysis could be completed for this group. RettBASE
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provides a list of 578 individuals with CDKL5 variants,
and only 308 of the probands are considered with pathogenic (n = 224), likely pathogenic (n = 41), or variant of
unknown significance (n = 43) alterations. The limited
sample size largely restrains the effectiveness of statistical analysis, and the results might be affected by data distribution and dispersion as well (Figure S1). Appropriate
parametric or nonparametric methods need to be selected
for adequate analysis.

5

|

CONC LUSION

The results from our study extend the understanding of
the pathogenesis of RTT and RTT-related syndromes by
providing insight into the preferential XCI of parental alleles in this patient cohort (paternal preferential inactivation in classic RTT and maternal preferential inactivation
in CDD). Our results suggest that in classic RTT the paternal X chromosome frequently carries de novo MECP2
pathogenic alterations while also being preferentially inactivated in XCI assays, and in CDD the maternal X chromosome is preferentially inactivated. We also identified
that recurrent pathogenic MECP2 variants are more commonly associated with XCI skewing in individuals with
classic RTT. Further studies are needed to explore potential clinical implications of these findings.
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